Literature DB >> 23378270

Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development.

Jim Jinn-Chyuan Sheu1, Jung Hye Choi, Bin Guan, Fuu-Jen Tsai, Chun-Hung Hua, Ming-Tsung Lai, Tian-Li Wang, Ie-Ming Shih.   

Abstract

Chromosome 11q13.5 containing RSF1 (HBXAP), a gene involved in chromatin remodelling, is amplified in several human cancers including ovarian carcinoma. Our previous studies demonstrated requirement of Rsf-1 for cell survival in cancer cells, which contributed to tumour progression; however, its role in tumourigenesis has not yet been elucidated. In this study, we co-immunoprecipitated proteins with Rsf-1 followed by nanoelectrospray mass spectrometry and identified cyclin E1, besides SNF2H, as one of the major Rsf-1 interacting proteins. Like RSF1, CCNE1 is frequently amplified in ovarian cancer, and both Rsf-1 and cyclin E1 were found co-up-regulated in ovarian cancer tissues. Ectopic expression of Rsf-1 and cyclin E1 in non-tumourigenic TP53(mut) RK3E cells led to an increase in cellular proliferation and tumour formation by activating cyclin E1-associated kinase (CDK2). Tumourigenesis was not detected if either cyclin E1 or Rsf-1 was expressed, or they were expressed in a TP53(wt) background. Domain mapping showed that cyclin E1 interacted with the first 441 amino acids of Rsf-1. Ectopic expression of this truncated domain significantly suppressed G1/S-phase transition, cellular proliferation, and tumour formation of RK3E-p53(R175H) /Rsf-1/cyclin E1 cells. The above findings suggest that Rsf-1 interacts and collaborates with cyclin E1 in neoplastic transformation and TP53 mutations are a prerequisite for tumour-promoting functions of the RSF/cyclin E1 complex.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23378270      PMCID: PMC4353404          DOI: 10.1002/path.4147

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  49 in total

1.  MASCOT: multiple alignment system for protein sequences based on three-way dynamic programming.

Authors:  M Hirosawa; M Hoshida; M Ishikawa; T Toya
Journal:  Comput Appl Biosci       Date:  1993-04

2.  Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.

Authors:  Neali D Hendrix; Rong Wu; Rork Kuick; Donald R Schwartz; Eric R Fearon; Kathleen R Cho
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

3.  DRO1, a gene down-regulated by oncogenes, mediates growth inhibition in colon and pancreatic cancer cells.

Authors:  Guido T Bommer; Claudia Jäger; Eva-Maria Dürr; Sebastian Baehs; Sören T Eichhorst; Thomas Brabletz; Gang Hu; Thomas Fröhlich; Georg Arnold; Dagmar C Kress; Burkhard Göke; Eric R Fearon; Frank T Kolligs
Journal:  J Biol Chem       Date:  2004-11-24       Impact factor: 5.157

4.  Rsf-1 overexpression correlates with poor prognosis and cell proliferation in colon cancer.

Authors:  Shuli Liu; Qianze Dong; Enhua Wang
Journal:  Tumour Biol       Date:  2012-04-20

5.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

6.  Sustained expression of Mect1-Maml2 is essential for tumor cell growth in salivary gland cancers carrying the t(11;19) translocation.

Authors:  T Komiya; Y Park; S Modi; A B Coxon; H Oh; F J Kaye
Journal:  Oncogene       Date:  2006-05-01       Impact factor: 9.867

7.  Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.

Authors:  Pedro P Medina; Octavio A Romero; Takashi Kohno; Luis M Montuenga; Ruben Pio; Jun Yokota; Montse Sanchez-Cespedes
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

8.  Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors.

Authors:  F Courjal; G Louason; P Speiser; D Katsaros; R Zeillinger; C Theillet
Journal:  Int J Cancer       Date:  1996-08-22       Impact factor: 7.396

9.  Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.

Authors:  Dariush Etemadmoghadam; Anna deFazio; Rameen Beroukhim; Craig Mermel; Joshy George; Gad Getz; Richard Tothill; Aikou Okamoto; Maria B Raeder; Paul Harnett; Stephen Lade; Lars A Akslen; Anna V Tinker; Bianca Locandro; Kathryn Alsop; Yoke-Eng Chiew; Nadia Traficante; Sian Fereday; Daryl Johnson; Stephen Fox; William Sellers; Mitsuyoshi Urashima; Helga B Salvesen; Matthew Meyerson; David Bowtell
Journal:  Clin Cancer Res       Date:  2009-02-03       Impact factor: 12.531

10.  Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma.

Authors:  Ie-Ming Shih; Kentaro Nakayama; Gang Wu; Naomi Nakayama; Jinghui Zhang; Tian-Li Wang
Journal:  Mod Pathol       Date:  2011-01-14       Impact factor: 7.842

View more
  25 in total

1.  Prognostic value of rsf-1/hbxap in human solid tumors: a meta-analysis of cohort studies.

Authors:  Jiayuan Wu; Liren Hu; Fenping Wu; Taiping He
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.

Authors:  Rajmohan Murali; Pier Selenica; David N Brown; R Keira Cheetham; Raghu Chandramohan; Nidia L Claros; Nancy Bouvier; Donavan T Cheng; Robert A Soslow; Britta Weigelt; W Glenn McCluggage
Journal:  Histopathology       Date:  2019-01-15       Impact factor: 5.087

3.  Remodeling and spacing factor 1 overexpression is associated with poor prognosis in renal cell carcinoma.

Authors:  Xiuwei Zhang; Dongwei Xue; Fengxia Hao; Lingling Xie; Jiani He; Junda Gai; Yuhui Liu; Hongtao Xu; Qingchang Li; Enhua Wang
Journal:  Oncol Lett       Date:  2018-01-15       Impact factor: 2.967

4.  Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer.

Authors:  Jie Ren; Qiu-Chen Chen; Feng Jin; Hui-Zhe Wu; Miao He; Lin Zhao; Zhao-Jin Yu; Wei-Fan Yao; Xiao-Yi Mi; En-Hua Wang; Min-Jie Wei
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

5.  Integration of genomic data enables selective discovery of breast cancer drivers.

Authors:  Félix Sanchez-Garcia; Patricia Villagrasa; Junji Matsui; Dylan Kotliar; Verónica Castro; Uri-David Akavia; Bo-Juen Chen; Laura Saucedo-Cuevas; Ruth Rodriguez Barrueco; David Llobet-Navas; Jose M Silva; Dana Pe'er
Journal:  Cell       Date:  2014-11-26       Impact factor: 41.582

6.  MicroRNA miR-16-1 regulates CCNE1 (cyclin E1) gene expression in human cervical cancer cells.

Authors:  Ma Isabel Zubillaga-Guerrero; Luz Del Carmen Alarcón-Romero; Berenice Illades-Aguiar; Eugenia Flores-Alfaro; Víctor Hugo Bermúdez-Morales; Jessica Deas; Oscar Peralta-Zaragoza
Journal:  Int J Clin Exp Med       Date:  2015-09-15

7.  Rsf-1 overexpression serves as a prognostic marker in human hepatocellular carcinoma.

Authors:  Chengyao Xie; Lin Fu; Lingling Xie; Nan Liu; Qingchang Li
Journal:  Tumour Biol       Date:  2014-05-06

8.  Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker.

Authors:  Hui Li; Yi Zhang; Yue Zhang; Xue Bai; Yang Peng; Ping He
Journal:  Tumour Biol       Date:  2014-03-01

9.  Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

Authors:  Alison M Karst; Paul M Jones; Natalie Vena; Azra H Ligon; Joyce F Liu; Michelle S Hirsch; Dariush Etemadmoghadam; David D L Bowtell; Ronny Drapkin
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

Review 10.  Epigenomic regulation of oncogenesis by chromatin remodeling.

Authors:  R Kumar; D-Q Li; S Müller; S Knapp
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.